# Sisonke (Together): OPEN LABEL TRIAL COVID-19

> **NCT04838795** · PHASE3 · COMPLETED · sponsor: **Wits Health Consortium (Pty) Ltd** · enrollment: 477102 (actual)

## Conditions studied

- SARS (Severe Acute Respiratory Syndrome)

## Interventions

- **BIOLOGICAL:** To monitor the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine

## Key facts

- **NCT ID:** NCT04838795
- **Lead sponsor:** Wits Health Consortium (Pty) Ltd
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-17
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-03-31
- **Target enrollment:** 477102 (ACTUAL)
- **Last updated:** 2022-08-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04838795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04838795, "Sisonke (Together): OPEN LABEL TRIAL COVID-19". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04838795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*